

No. 8107 P. 23

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Tami HAREL et al.

Serial No.: 10/526,708

Filed: September 20, 2005

For: **BLOOD GLUCOSE LEVEL CONTROL**

Examiner: FLORY, CHRISTOPHER A

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

www.pearsoned.com

Group Art Unit: 3762

Attorney Docket: 34490

TERMINAL DISCLAIMER

Sir:

The owner, MetaCure NV, of Curacao, Netherlands Antilles, having 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior U.S. Patent Application No.

10/804,560. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction,


is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Authorization to charge the above Terminal Disclaimer fee of \$130 (LBE), and any other fees to Deposit Account 50-1407. A duplicate of this form is enclosed.

12/20/2007 ATRAN1 00000023 501407 10526708
01 FC:1814 130.00 DA

Respectfully submitted,


Martin D. Moynihan
Registration No. 40,338

December 18, 2007